A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing existing literature without systematic review or meta-analysis methodology
PubMed 31565876 · doi:10.3803/EnM.2019.34.3.247
What was done
The authors reviewed available literature evaluating the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) on human body composition, specifically fat mass and lean body mass.
What was found
Weight loss with both drug classes predominantly comprised fat mass loss. However, in more than half of identified studies, lean body mass reduction accounted for 20% to 50% of total weight lost. No clear differences were observed between GLP-1RAs and SGLT2is, matching proportions observed in diet-induced weight loss and bariatric surgery.
Why it matters
Because lean mass and skeletal muscle are vital for cardiometabolic health and physical function, pharmacological weight loss from these agents may require adjunctive interventions, such as structured exercise, to preserve muscle mass.
Limits
The abstract describes a narrative review with no search strategy details, exact study count, or sample sizes reported. Significant heterogeneity was noted across included studies, and specific measurement techniques for body composition were not detailed.
Cited by
- supports Studies in mice and humans indicate that lean mass loss during GLP-1 receptor agonist treatment is comparable to caloric restriction and bariatric surgery, rather than direct drug-induced muscle destruction.